Steiner G (December 2007). "Atherosclerosis in type 2 diabetes: a role for fibrate therapy?". Diab Vasc Dis Res4 (4): 368–74. PMID18158710. doi:10.3132/dvdr.2007.067.
Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, Pilote L, Genest J, Eisenberg MJ (2009). "Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review". Am J Med122 (10): 962.e1–962.e8. PMID19698935. doi:10.1016/j.amjmed.2009.03.030.
Jun M, Foote C, Lv J, et al. (2010). "Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis". Lancet375 (9729): 1875–1884. doi:10.1016/S0140-6736(10)60656-3.
Wysocki J, Belowski D, Kalina M, Kochanski L, Okopien B, Kalina Z (2004). "Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome". International Journal of Clinical Pharmacology and Therapeutics42 (4): 212–217. PMID15124979. doi:10.5414/cpp42212.
"Aging". www.impactaging.com. Arquivado dende o orixinal o 04 de marzo de 2016. Consultado o 13 April 2018.
nih.gov
ncbi.nlm.nih.gov
Steiner G (December 2007). "Atherosclerosis in type 2 diabetes: a role for fibrate therapy?". Diab Vasc Dis Res4 (4): 368–74. PMID18158710. doi:10.3132/dvdr.2007.067.
Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, Pilote L, Genest J, Eisenberg MJ (2009). "Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review". Am J Med122 (10): 962.e1–962.e8. PMID19698935. doi:10.1016/j.amjmed.2009.03.030.
Wysocki J, Belowski D, Kalina M, Kochanski L, Okopien B, Kalina Z (2004). "Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome". International Journal of Clinical Pharmacology and Therapeutics42 (4): 212–217. PMID15124979. doi:10.5414/cpp42212.